Načítá se...
What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?
The prevalence of type 2 diabetes continues to increase, along with a proliferation of glucose-lowering treatment options. There is universal agreement in the clinical community for the use of metformin as the first-line glucose-lowering therapy for the majority of patients. However, controversy exi...
Uloženo v:
| Vydáno v: | Diabetes Ther |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Healthcare
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6778564/ https://ncbi.nlm.nih.gov/pubmed/31410711 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-00678-z |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|